Bio­haven touts surge in Nurtec sales ahead of Pfiz­er takeover

For­get buy­er’s re­morse, Pfiz­er is like­ly feel­ing pret­ty good about its $11.6 bil­lion Bio­haven takeover deal fol­low­ing re­ports of a 57% sales boost for mi­graine med Nurtec.

Bio­haven re­port­ed in Q2 re­sults on Fri­day that it’s cleared the nec­es­sary an­titrust hur­dles to move for­ward with the sale of its cal­ci­tonin gene-re­lat­ed pep­tide (CGRP) as­sets to Pfiz­er. How­ev­er, be­cause the com­pa­ny is “fo­cused on work­streams re­lat­ed to the clos­ing” of the deal, it did not host a call with an­a­lysts and in­vestors.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN